

# Nimesulide: a vulture-toxic drug

*Summary of evidence that nimesulide is toxic to vultures; and that meloxicam, an alternative to nimesulide, is not toxic to vultures as well as a safe and effective veterinary drug*

*Version 2: June 2021*



*SAVE is an international consortium of conservation and research organisations whose mission is to respond to the vulture crisis in Asia by striving to halt vulture population declines and working to minimise their negative impacts on ecological and human health. For further details go to [www.save-vultures.org](http://www.save-vultures.org)*

## **Nimesulide is toxic to *Gyps* vultures; however, meloxicam is not toxic to *Gyps* vultures and an effective alternative to nimesulide for veterinary purposes**

### *Aim*

This paper, intended for decision-makers involved in drug licensing, presents evidence of the toxicity of nimesulide, a non-steroidal anti-inflammatory drug (NSAID), to *Gyps* vultures; and the safety, in both vultures and domesticated animals, and effectiveness, in domesticated animals, of meloxicam, an alternative NSAID.

### *Executive summary*

1. The NSAID nimesulide has been found in dead wild *Gyps* vultures.
2. Wild vultures are exposed to NSAIDs when feeding on carcasses of domesticated ungulates treated with these drugs shortly before death.
3. In two separate studies, nine white-rumped vultures *Gyps bengalensis* were found dead in the wild, and tested positive for nimesulide. Eight of these also showed visceral gout (i.e. a clinical sign of renal failure in birds). One of these tested positive for meloxicam as well as nimesulide, but another vulture that tested positive for meloxicam and not nimesulide showed no visceral gout. Diclofenac was not detected in any of the eight vultures showing visceral gout and nimesulide.
4. In contrast to nimesulide, the NSAID meloxicam has been shown to be non-toxic to *Gyps* vultures above the maximum level of exposure (MLE).
5. The MLE of a given drug to a *Gyps* vulture is intended to reflect the largest dose of the drug likely to be encountered by that species in the wild. The MLE for an NSAID is calculated from the body weight of a given vulture species, the weight of a large meal for that species and highest tissue-specific residue concentration of the NSAID in tissues of a domesticated ungulate treated with the drug. The MLE for meloxicam was

calculated assuming that cattle in India may typically be dosed with twice the recommended amount.

6. Two experiments showed that oral doses of meloxicam above the MLE did not cause hyperuricemia or any other ill effects in 50 individual *Gyps* vultures from three species: African white-backed vultures *Gyps africanus*, Asian white-backed vultures *Gyps bengalensis* and long-billed vultures *Gyps indicus*. These experiments also showed that tissues from cattle and buffalo dosed with meloxicam with some doses at the MLE did not cause hyperuricemia or any other ill effects in *Gyps* vultures. Further, oral doses of meloxicam above the MLE did not cause hyperuricemia or any other ill effects in Egyptian vultures *Neophron percnopterus*, cattle egrets *Bubulcus ibis*, crows *Corvus spp.* and common myna *Acridotheres tristis*, which also scavenge.
7. Meloxicam is manufactured in Bangladesh, India, Nepal and Pakistan. It has been shown to be an effective treatment for pain, inflammation, stress and dysfunction in a variety of veterinary and husbandry situations. In addition, meloxicam has been shown to increase immune response, pregnancy rate, cow productivity and calf productivity. Negative or mixed effects of meloxicam are rare. In contrast, very few studies have examined the effectiveness and safety of nimesulide to domesticated animals. A single study has compared meloxicam and nimesulide; and found a positive effect for meloxicam and negative effect for nimesulide.
8. To conserve critically endangered *Gyps* vultures, veterinary nimesulide and multipledose vials of human nimesulide should be banned throughout South Asia. Such a comprehensive ban would not impact livestock healthcare because meloxicam is a safe, effective and widely available alternative to nimesulide.

### *Supporting evidence*

We present six lines of supporting evidence.

1. Between 2002 and 2015, wildlife forensic investigations examined 62 dead *Gyps* vultures in India. Post-mortem examination included liquid chromatography mass spectrometry screening

in 48 vultures. Diclofenac was screened in all years and another eight NSAIDs were screened from 2005 onwards. The organs of 29 vultures screened for NSAIDs showed severe visceral gout. Of these, 25 were positive for diclofenac, three were positive for nimesulide and one was positive for nimesulide and meloxicam. Among the 17 vultures screened for NSAIDs that did not show visceral gout, one was positive for nimesulide, one was positive for meloxicam and 15 were not positive for any NSAID. Further details in pages 7-9.

2. Four vultures were found dead in the Indian state of Gujarat in 2019. Post-mortem examination revealed that all four birds displayed evidence of renal failure, i.e. visceral gout. Toxicological analysis could find no evidence (i.e. all were below the level of detection) for the presence of 32 pesticides. Of 14 drugs tested (13 NSAIDs plus paracetamol), the only drug at concentrations above the level of detection was nimesulide. The concentration of nimesulide in the four birds was 17.2 – 792.1 ng g<sup>-1</sup> in the liver, 61.0 – 1395.4 ng g<sup>-1</sup> in the kidney and 195.9 – 1340.7 ng g<sup>-1</sup> in the gut contents.

3. In an experiment, two African Cape Vultures *Gyps coprotheres* were given doses orally of nimesulide at the maximum level of exposure that vultures are likely to encounter in cattle carcasses. Both vultures died within 30 hours of dosing. Uric acid concentrations increased 27-79-fold on pre-dose levels. Both birds showed evidence of visceral gout.

4. The effect of meloxicam on *Gyps* vultures was examined in a six-phase partially controlled experiment conducted in South Africa and India. Phases were: (1-2) 10 African white-backed vultures *Gyps africanus* were given an oral dose of meloxicam at 0.5-1.0 mg/kg body weight (bw); (3-4) 40 African white-backed vultures *Gyps africanus* were given an oral dose of meloxicam at 2.0 mg/kg bw; (5) six African white-backed vultures *Gyps africanus* were twice fed meloxicam-contaminated cattle tissue and once given an oral dose of meloxicam at >0.01-1.98 and 1.18-2.45 mg/kg bw, respectively; and (6) six Asian white-backed vultures *Gyps bengalensis* and four long-billed vultures *Gyps indicus* were given an oral dose of meloxicam of 0.5-2.0 mg/kg bw. The maximum level of exposure (MLE) of meloxicam to Asian white-backed vulture

*Gyps bengalensis* was calculated as 1.83 mg/kg bw. In all Phases, all meloxicam-treated vultures survived with no ill effects. All control vultures survived. Uric acid concentrations in plasma in all meloxicam-treated vultures remained within the normal range. Further details in pages 10-13.

5. The effect of meloxicam on *Gyps* vultures and other common scavenging birds was examined in a three-phase controlled experiment in India. Phases were: (1) six white-rumped vultures *Gyps bengalensis* and four Long-billed vultures *Gyps indicus* were given an oral dose of meloxicam at 0.5 or 2.0 mg/kg bw; (2) five Egyptian vultures *Neophron percnopterus*, five cattle egrets *Bubulcus ibis*, five crows *Corvus spp.* and five common myna *Acridotheres tristis* were given an oral dose of meloxicam at 2.0 mg/kg bw; and (3) 19 Asian white-backed vultures *Gyps bengalensis* and two long-billed vultures *Gyps indicus* were fed tissue from buffalo dosed with meloxicam. In all Phases, all meloxicam-treated birds survived with no ill effects. All control birds survived. Uric acid and ALT concentrations in serum in all meloxicam-treated birds was not significantly different to that of control birds. Further details in pages 14-16.

6. A review of studies reporting an effect of nimesulide and meloxicam in veterinary and husbandry situations found a single study for nimesulide and 117 studies for meloxicam. The single study examining the effect of nimesulide compared it to that of meloxicam: while meloxicam had a positive effect; nimesulide had a negative effect. Overall, 79% of studies examining meloxicam treatment reported a positive effect. Meloxicam showed positive effects in cattle, buffalo, horse, goat, sheep and dog; and during castrating, dehorning, general care, handling, infections, limb injuries, reproducing and surgery. In these animals and situations, meloxicam decreased pain, inflammation, stress and dysfunction; increased recovery rate, immune response, pregnancy rate and productivity; and generally resulted in no complications. The proportion of studies examining meloxicam treatment that reported a mixed effect, negative effect, no effect and no conclusion were 9, 3, 7 and 2%, respectively. The studies that reported a negative effect of meloxicam treatment resulted in pregnancy complications, but another eleven studies reported a positive effect of meloxicam treatment on pregnancy rate.

Nimesulide treatment was not examined for pregnancy complications. Further details in pages 17-23.

*Specific details*

Chemical name: **nimesulide**

Systematic name: *N*-(4-Nitro-2-phenoxyphenyl)methanesulfonamide

Formula: C<sub>13</sub>H<sub>12</sub>N<sub>2</sub>O<sub>5</sub>S

Molar mass: 308.311 g/mol

Typical formulation: 100, 200 or 400 mg/ml injections in 15 or 30 ml vials, 400 or 1000 mg bolus

Example products (manufacturers): Bangladesh – products are imported

India – Bolin NP (Ruby), Care-NP (Iskon), Diclodec NP (ESPEE), Doloban (Akums), King-NP (Safecon), Nimovet (Indian immunological/Santax), Nimsonex Vet (Stanex), Noxalgin (Nucare), Oxalgin NP (Zydac/ACME)

Nepal – Indian products are imported

Pakistan – products may be imported

Chemical name: **meloxicam**

Systematic name: 4-hydroxy-2-methyl-*N*-(5-methyl-2-thiazolyl)-2*H*-1,2-benzothiazine-3carboxamide-1,1-dioxide

Formula: C<sub>14</sub>H<sub>13</sub>N<sub>3</sub>O<sub>4</sub>S<sub>2</sub>

Molar mass: 351.403 g/mol

Typical formulation: 5 or 10 mg/ml injection in 30, 50 or 100 ml vials; and 100 mg bolus

Example products (manufacturers):

Bangladesh – Mel-Vet (ACME), Meximol (Ethical drugs), MP-Vet (Chemist Laboratories)

India – Diclovet-M and Melodic (Umedica), Melonex (Intas), Melosafe and Meloxicon (Safecon), Melovet (Zee), Proxyvet-MP (Health Biotech), Xyclofen (Iskon)

Nepal – Melocam (CTL), Melox (Medivet), Molfen (Qumed)

Pakistan – Camilox and Meloxi-10 (Selmore), Diclostare (Star), Diclosym and Melocsym (Symans), Metrym (Nawan)

## **1. Post mortem examination of wild *Gyps* vultures finds visceral gout in association with nimesulide residue and not diclofenac residue**

### *Published source*

Cuthbert, R. J., Taggart, M. A., Saini, M., Sharma, A., Das, A., Kulkarni, M. D., Deori, P., Ranade, S., Shringarpure, R. N. Galligan, T. H. and Green, R. E. (2015). Continuing mortality of vultures in India associated with illegal veterinary use of diclofenac and a potential threat from nimesulide *Oryx* 50: 104-112.

### *Background*

Diclofenac kills vultures through acute renal failure. In vultures, acute renal failure presents as visceral gout (i.e., uric acid deposits on organs and within kidney tubules). Nimesulide is used to treat domesticated ungulates in South Asia. This examination of carcasses of wild vultures was carried out in India.

### *Action*

Between 2000 and 2012, carcasses of *Gyps* vultures were collected opportunistically from nine Indian states. Post mortem examination focussing on detecting visceral gout was conducted on all carcasses found. Liver and kidney tissue were sampled from most carcasses for NSAIDs screening using liquid chromatography mass spectrometry. For carcasses examined in 2005-2011, samples were screened for nine NSAIDs, including diclofenac, meloxicam and nimesulide.

For carcasses examined 2000-2004, samples were screened for only diclofenac.

### *Findings*

Sixty-two carcasses of five *Gyps* species were examined for visceral gout. Of these, 48 carcasses of five *Gyps* species were also screened for NSAIDs.

Diclofenac residue and visceral gout were found in 25 carcasses.

Nimesulide residue was found in 5 carcasses; and visceral gout was found in 4 out of these 5 carcasses. Diclofenac residue was not found in any of these carcasses; however, 1 carcass with nimesulide residue and visceral gout also had meloxicam residue.

Another carcass had meloxicam residue but no visceral gout.

### *Conclusion*

Nimesulide caused acute renal failure and death in *Gyps* vultures.

*Key figure*

Co-occurrence of visceral gout and residue of NSAIDs in carcasses of wild *Gyps* vultures collected in India during 2000-2011. Results are shown separately for a period when assays were only performed on diclofenac (2000-2004) and a later period (2005-2011) when eight other NSAIDs were also assayed. Among these other NSAIDs only meloxicam and nimesulide were detected. The number of fledglings, juveniles, adults and individuals of unknown age, respectively, are shown in brackets.

| Species                | Gout | Diclofenac   | Nimesulide  | Meloxicam   | Nimesulide<br>& meloxicam | No NSAID    |
|------------------------|------|--------------|-------------|-------------|---------------------------|-------------|
| <b>2000–2004</b>       |      |              |             |             |                           |             |
| <i>G. fulvus</i>       | Yes  | 0            |             |             |                           | 0           |
|                        | No   | 0            |             |             |                           | 1 (0,1,0,0) |
| <i>G. himalayensis</i> | Yes  | 0            |             |             |                           | 0           |
|                        | No   | 0            |             |             |                           | 1 (0,1,0,0) |
| <i>G. indicus</i>      | Yes  | 6 (0,5,1,0)  |             |             |                           | 0           |
|                        | No   | 0            |             |             |                           | 3 (0,2,1,0) |
| <i>G. bengalensis</i>  | Yes  | 7 (0,3,4,0)  |             |             |                           | 0           |
|                        | No   | 0            |             |             |                           | 4 (1,1,2,0) |
| All species            | Yes  | 13 (0,8,5,0) |             |             |                           | 0           |
|                        | No   | 0            |             |             |                           | 9 (1,5,3,0) |
| <b>2005–2011</b>       |      |              |             |             |                           |             |
| <i>G. fulvus</i>       | Yes  | 0            | 0           | 0           | 0                         | 0           |
|                        | No   | 0            | 0           | 0           | 0                         | 0           |
| <i>G. himalayensis</i> | Yes  | 1 (0,1,0,0)  | 0           | 0           | 0                         | 0           |
|                        | No   | 0            | 0           | 0           | 0                         | 1 (0,1,0,0) |
| <i>G. indicus</i>      | Yes  | 0            | 0           | 0           | 0                         | 0           |
|                        | No   | 0            | 0           | 0           | 0                         | 1 (0,1,0,0) |
| <i>G. bengalensis</i>  | Yes  | 11 (2,1,8,0) | 3 (0,1,1,1) | 0           | 1 (0,0,1,0)               | 0           |
|                        | No   | 0            | 1 (0,0,1,0) | 1 (0,0,0,1) | 0                         | 4 (1,3,0,0) |
| All species            | Yes  | 12 (2,2,8,0) | 3 (0,1,1,1) | 0           | 1 (0,0,1,0)               | 0           |
|                        | No   | 0            | 1 (0,0,1,0) | 1 (0,0,0,1) | 0                         | 6 (1,5,0,0) |

## **2. Further evidence that nimesulide is toxic to vultures: post-mortem examination of more wild White-rumped Vultures *Gyps bengalensis* finds visceral gout in association with nimesulide and not diclofenac residues.**

### *Source*

Nambirajan, K., Muralidharan, S., Ashimkumar, A.R. & Jadhav, S. 2021. Nimesulide poisoning in white-rumped vulture *Gyps bengalensis* in Gujarat, India. *Environmental Science and Pollution Research*, <https://doi.org/10.1007/s11356-021-14702-y>

### *Background*

Diclofenac kills vultures through acute renal failure which, in vultures, as presents as visceral gout (i.e. uric acid deposits on organs and within kidney tubules), and was responsible for the catastrophic declines of *Gyps* vulture populations in south Asia. Another NSAID nimesulide is also used to treat domesticated ungulates in South Asia, residues of which have previously been found in dead vultures with visceral gout.

### *Action*

In 2019, four dead white-rumped vultures were found in the Indian state of Gujarat, in two separate mortality incidents. Post-mortems were carried out, and tissue samples from the liver, kidney and gut contents analysed for 32 toxic pesticides and 13 different NSAIDs, and paracetamol, using liquid chromatography mass spectrometry.

### *Findings*

Evidence of visceral gout was found during post-mortem examination of all four vultures. Residues of 32 pesticides were all below the level of detection in the kidney, liver and gut contents of all four vultures. Of the 14 drugs analysed, only residues of nimesulide were detected in all tissues investigated; all others were below the level of detection. The

concentration of nimesulide in the four birds was 17.2 – 792.1 ng g<sup>-1</sup> in the liver, 61.0 – 1395.4 ng g<sup>-1</sup> in the kidney and 195.9 – 1340.7 ng g<sup>-1</sup> in the gut contents.

### Conclusion


Nimesulide caused acute renal failure and death in *Gyps* vultures.

### Key figures

Environ Sci Pollut Res

**Table 2** Concentration of nimesulide (ng/g, wet weight) recorded in the tissues of white-rumped vultures received dead from Gujarat during 2019

| Incident/date/place  | Vulture Id             | Organ       | Concentration of nimesulide (ng/g, wet weight) | Uric acid crystal/visceral gout |
|--|------------------------|-------------|--|---------------------------------|
| Incident 1<br>4th January 2019<br>Sanand, Gujarat                          | White-rumped vulture 1 | Liver       | 792.1  | Present                         |
|  |                        | Kidney      | 1395.4   |                                 |
|  |                        | Gut content | 1108.2   |                                 |
|  | White-rumped vulture 2 | Liver       | 112.5  | Present                         |
|  |                        | Kidney      | 234.2  |                                 |
|  |                        | Gut content | 1340.7   |                                 |
| Incident 2<br>7th October 2019<br>Wild Ass Sanctuary, Dhrangadhra, Gujarat | White-rumped vulture 1 | Liver       | 731.6  | Present                         |
|  |                        | Kidney      | 61.0   |                                 |
|  |                        | Gut content | 424.8  |                                 |
|  | White-rumped vulture 2 | Liver       | 17.1   | Present                         |
|  |                        | Kidney      | 107.7  |                                 |
|  |                        | Gut content | 195.9  |                                 |



**Fig. 1** White chalky uric acid deposit on both the liver lobes of a white-rumped vulture collected from Sanand, Gujarat

### **3. An experiment finds that doses of nimesulide at the maximum level of exposure causes kidney failure, elevation of blood uric acid levels, visceral gout and death in African Cape Vultures *Gyps coprotheres*.**

#### *Source*

Galligan, T.H., Green, R.E., Wolter, K., Taggart, M.A., Duncan, N., Mallord, J.W., Alderson, D., Li, Y. & Naidoo, V. *In review*. The non-steroidal anti-inflammatory drug nimesulide kills *Gyps* vultures at concentrations found in the muscle of treated cattle.

#### *Background*

Residues of the NSAID nimesulide, in association with visceral gout, have been found in the tissues taken from the carcasses of White-rumped Vultures *Gyps bengalensis*, and is therefore likely to be the cause of death of these birds, and therefore toxic to vultures. However, to confirm the toxicity of NSAIDs to *Gyps* vultures, experimental safety testing of drugs needs to be carried out.

#### *Action*

Initially, a pharmacokinetic study of nimesulide in cattle was carried out to estimate the maximum level of exposure (MLE) of the drug likely to be encountered by vultures in the wild. Firstly, four cattle were injected with nimesulide at the standard dose ( $2 \text{ mg kg}^{-1}$ ), and blood samples taken at regular intervals to identify the time ( $T_{max}$ ) at which maximum concentrations of the drug were reached. Secondly, double the recommended dose (i.e.  $4 \text{ mg kg}^{-1}$ , to simulate the behaviour of livestock owners in India) was given to a further four cattle, which were slaughtered at  $T_{max}$ , and tissue samples collected from the neck (injection site), hindquarters, liver and kidney to measure nimesulide concentrations. The MLE was estimated based on mean daily energy use and the maximum likely meal consumed by a vulture. Two African Cape Vultures *G. coprotheres*, a species known to be susceptible to NSAID poisoning and therefore a suitable surrogate for Asian *Gyps* vultures, were given a dose of injectable nimesulide orally

based on the estimated MLE; two other vultures (control group) were given an oral dose of water. Blood samples were taken at regular intervals up to 48 hours after dosing and analysed for nimesulide, uric acid and other biochemical parameters. Post-mortems were carried out on any vulture that died during the experiment.


### Findings

Both vultures given nimesulide died within 30 hours after dosing; both vultures within the control group were alive and well after 48 hours when the experiment was terminated. Uric acid concentrations showed a 27 – 79-fold increase over their baseline values. Post-mortem examination found visceral gout in both vultures.

### Conclusion

Nimesulide is toxic to *Gyps* vultures.

### Key figures






Figure 2: Change over time in plasma alanine transferase (A) and uric acid (C) in two vultures (solid squares = G32745 and open circles = G32746) treated with nimesulide at  $17.58 \text{ mg kg}^{-1} \text{ bw}$ . G32746 likely received a lower unknown dose as it was observed expelling liquid immediately after dosing. Also shown is the normal range of concentrations for each biochemical delineated by the lowest and highest measurements taken from two control vultures (dashed lines).

#### **4. An experiment finds doses above the MLE of meloxicam to Asian white-backed vultures *Gyps bengalensis* does not cause kidney failure, death or elevation of blood uric acid levels in African and Asian *Gyps* vultures**

##### *Source*

Swan, G., Naidoo, V., Cuthbert, R., Green, R. E., Pain, D. J., Swarup, D., Prakash, V., Taggart M. A., Bekker, L., Das, D., Diekmann, J., Diekmann, M., Killian, E., Meharg, A., Patra, R. C., Saini, M. and Wolter, K. (2006). Removing the threat of diclofenac to critically endangered Asian vultures. *PLoS Biology* DOI: 10.1371/journal.pbio.0040066.

##### *Background*

A previous questionnaire survey on the use of NSAIDs in vultures, found no mortality in 39 cases of meloxicam treatment involving six species of *Gyps* vultures. This experiment was undertaken to further examine the toxicity of meloxicam to *Gyps* vultures.

##### *Action*

The effect of meloxicam on *Gyps* vultures was examined in a six-phase partially controlled experiment in South Africa and India.

African and Asian *Gyps* vultures were used. The African white-backed vulture *Gyps africanus* and the Asian white-backed vulture *Gyps bengalensis* are of similar size (4-7 and 3.5-7.5 kg, respectively).

One injectable meloxicam product, manufactured and purchased in India, was used. Double the recommended dose for cattle in India was used to reflect frequent overdosing behaviour in India.

Phases 1-2: 10 African white-backed vultures were given an oral dose of meloxicam at 0.5-1.0 mg/kg body weight (bw); and six African white-backed vultures were given sterilised water.

Phases 3-4: 40 African white-backed vultures *Gyps africanus* (including 21 wild vultures) were

given an oral dose of meloxicam at 2.0 mg/kg bw; and three captive and four wild African white-backed vultures *Gyps africanus* were given sterilised water.

Phase 5: six African white-backed vultures *Gyps africanus* were twice fed tissue from cattle dosed with meloxicam and once given an oral dose of meloxicam at >0.01-1.98 and 1.18-2.45 mg/kg bw, respectively. Meloxicam-contaminated cattle tissues were muscle and liver from three cattle given daily injections of meloxicam at 1 mg/kg bw for five days and slaughtered 8 h after the final dose.

Phase 6: six Asian white-backed vultures *Gyps bengalensis* and four long-billed vultures *Gyps indicus* were given an oral dose of meloxicam 0.5-2.0 mg/kg bw; and two Asian white-backed vultures *Gyps bengalensis* and three long-billed vultures *Gyps indicus* were given sterilised water.

Blood samples were taken from all vultures in Phases 1-5 before the experiment and at up to six time points up to 168 h after dosing. Serum was analysed for uric acid and three other biochemicals.

The maximum level of exposure of meloxicam to Asian white-backed vultures *Gyps bengalensis* was calculated using the average body weight (4.75 kg), estimated large meal weight (1.02 kg) and highest meloxicam residue concentration in cattle liver tissue (8.54 mg/kg bw); and was equal to 1.83 mg/kg bw.

### *Findings*


In all Phases, all meloxicam-treated vultures survived with no ill effects. All control vultures survived.

Uric acid concentrations in serum in all meloxicam-treated vultures remained within a 95% range calculated from measurements from these vultures before treatment and control vultures.

### *Conclusion*

Meloxicam is not toxic to *Gyps* vultures at the maximum level of exposure.

Key figure



The effect of administration of meloxicam and diclofenac by [oral dose] on uric acid in serum of vultures. Blue symbols show the ratio of the geometric mean (with 95% confidence interval) serum concentration of uric acid for a group of *Gyps* vultures treated with meloxicam to that for a control group sampled at the same time. Each group of blue symbols show the effects of increased doses of meloxicam, from left to right. Red symbols and vertical lines show the equivalent ratio but for vultures given diclofenac. See article for more detail.

## **5. An experiment finds doses above the MLE of meloxicam to Asian whitebacked vultures *Gyps bengalensis* does not cause kidney failure, death or elevation of blood uric acid levels in *Gyps* vultures and other common scavenging birds native to South Asia**

### *Source*

Swarup, D., Patra, R. C., Prakash, V., Cuthbert, R., Das, D., Avarti, P., Pain, D. J., Green, R. E., Sharma, A.K., Saini, M. Das, D. and Taggart M. A. (2007). Safety of meloxicam to critically endangered *Gyps* vultures and other scavenging birds of India. *Animal Conservation* 10: 192-198.

### *Background*

Meloxicam is not toxic to *Gyps* vultures. This experiment was undertaken to further examine the toxicity of meloxicam to *Gyps* vultures and other common scavenging birds of South Asia.

### *Action*

The effect of meloxicam on *Gyps* vultures and other common scavenging birds was examined in a three-phase controlled experiment in India.

One injectable meloxicam product, manufactured and purchased in India, was used. Double the recommended dose for buffalo in India was used to reflect frequent overdosing behaviour in India.

Phases 1: six Asian white-backed vultures *Gyps bengalensis* and four Long-billed vultures *Gyps indicus* were given an oral dose of meloxicam at 0.5 or 2.0 mg/kg body weight (bw); and two Asian white-backed vultures *Gyps bengalensis* and two Long-billed vultures *Gyps indicus* were given sterilised water.

Phases 2: five Egyptian vultures *Neophron percnopterus*, five cattle egrets *Bubulcus ibis*, five crows *Corvus spp.* and five common myna *Acridotheres tristis* were given an oral dose of meloxicam at 2.0 mg/kg bw; and four Egyptian vultures *Neophron percnopterus*, four cattle

egrets *Bubulcus ibis*, five crows *Corvus spp.* and five common myna *Acridotheres tristis* were given sterilised water.

Phase 3: 19 Asian white-backed vultures *Gyps bengalensis* and two long-billed vultures *Gyps indicus* were fed tissue from buffalo dosed with meloxicam; and five Asian white-backed vultures *Gyps bengalensis* were fed tissue from goats not dosed with meloxicam.

Meloxicam-contaminated buffalo tissues were muscle and liver representing doses of 0.3-2.1 mg/kg bw from two buffalo given daily injections of meloxicam at 1 mg/kg bw for five days and slaughtered 8 h after the final dose.

Blood samples were taken before dosing and 48h after dosing from all birds in Phases 1 and 2 (except common myna *Acridotheres tristis*); and only 48h after dosing from birds in Phase 3.

Serum was analysed for uric acid and other biochemical components. All birds were observed for seven days for symptoms of toxicity.


### *Findings*

In all Phases, all meloxicam-treated birds survived with no ill effects. All control birds survived. Uric acid and ALT concentrations in serum in all meloxicam-treated birds was significantly different to that of control birds.

### *Conclusion*

Meloxicam is not toxic to *Gyps* vultures and other common scavenging birds at the maximum level of exposure.

Key figure



Concentration of uric acid and ALT in serum of Egyptian vultures *Neophron percnopterus*, cattle egrets *Bubulcus ibis* and crows *Corvus spp.* given an oral dose of meloxicam at 2.0 mg/kg bw (filled columns) or sterilised water (open columns).

## **6. A review of the literature finds that meloxicam is a safe and effective treatment for domesticated animals**

### *Source*

Vulture-safe meloxicam is a safe and effective treatment for a variety of ailments in cattle (unpublished) Galligan, T. H., et al.

### *Background*

Meloxicam is not toxic to vultures. Therefore, meloxicam is vulture-safe alternative to ketoprofen. This review of literature was undertaken to assess the safety and effectiveness of meloxicam as an alternative to ketoprofen for the treatment of domesticated animals.

### *Action*

The PubMed literature databases (online and open access) were surveyed for *in vivo* experimental and clinical studies reporting an effect of ketoprofen and/or meloxicam in the following domesticated animals: cattle; water buffalo; horse; donkey; camel; goat; sheep; and dog.

### *Findings*

Among 118 studies: 117 reported an effect of meloxicam treatment; and 1 reported an effect of meloxicam and nimesulide treatment.

All studies were grouped into broad veterinary and husbandry situations for treatment (e.g. infection, surgery, reproducing); broad objectives of treatment (e.g. decrease pain, increase reproductive rate, no complications); and categorised as having a: positive effect; negative effect; mixed effect (partially positive and negative); no effect; or no conclusion.

A single study comparing meloxicam and nimesulide treatment in dogs reported a positive effect (decreased pain and inflammation) for meloxicam and negative effect (renal complications renal) for nimesulide.

A positive effect was reported in 79% of studies examining meloxicam treatment. The proportion of studies examining meloxicam treatment that reported a mixed effect, negative effect, no effect and no conclusion were 9, 3, 7 and 2%, respectively.

Meloxicam showed positive effects: in cattle, buffalo, horse, goat, sheep and dog; and during castrating, dehorning, general care, handling, infections, limb injuries, reproducing and surgery. In these situations, meloxicam decreased pain, inflammation, stress and dysfunction; increased recovery rate, immune response, pregnancy rate and productivity; and generally resulted in no complications.

Overall, three studies reported negative effects of meloxicam treatment resulting in pregnancy complications (one each in cattle, horse and sheep). However, eleven studies reported positive effects of meloxicam treatment resulting in no pregnancy complications (nine in cattle and two in sheep). Further, no study examined the effect of aceclofenac on pregnancy.

### *Conclusion*

Meloxicam is a safe and effective NSAID for use in a variety of veterinary and husbandry situations in a variety of animals.

*Key figure*

One-hundred and eighteen studies reported an effect of either meloxicam or meloxicam and nimesulide treatment in domesticated animals. Data provided are: NSAID(s) examined; reference for the study; domesticated animal; veterinary or husbandry situation; objective of treatment; experimental method; total sample size (n); and effect reported.

| NSAID                  | Study                 | Animal | Situation  | Objective                                    | Method         | n   | Effect  |
|------------------------|-----------------------|--------|------------|--|----------------|-----|---|
| Meloxicam & nimesulide | Borges et al. 2013    | Dog    | General    | No complications                             | not controlled | 24  | Positive for meloxicam, negative for nimesulide |
| Meloxicam              | Roberts et al. 2016   | Cattle | Castration | Decrease pain                                | controlled     | 83  | Mixed   |
| Meloxicam              | Roberts et al. 2015   | Cattle | Castration | Decrease pain                                | controlled     | 30  | Positive  |
| Meloxicam              | Olson et al. 2016     | Cattle | Castration | Decrease pain                                | controlled     | 60  | Positive  |
| Meloxicam              | Coetzee et al. 2012a  | Cattle | Castration | Decrease pain                                | controlled     | 258 | Positive  |
| Meloxicam              | Brown et al. 2015     | Cattle | Castration | Decrease pain and increase calf productivity | controlled     | 62  | Positive  |
| Meloxicam              | Repenning et al. 2013 | Cattle | Castration | Decrease pain and stress                     | controlled     | 157 | None  |
| Meloxicam              | Allen et al. 2013     | Cattle | Dehorning  | Decrease pain                                | controlled     | 30  | Positive  |
| Meloxicam              | Stewart et al. 2009   | Cattle | Dehorning  | Decrease pain                                | controlled     | 46  | Positive  |
| Meloxicam              | Clapp et al. 2015     | Cattle | Dehorning  | Decrease pain                                | not controlled | 25  | Mixed   |
| Meloxicam              | Theurer et al. 2012   | Cattle | Dehorning  | Decrease pain                                | not controlled | 12  | Positive  |
| Meloxicam              | Coetzee et al. 2012b  | Cattle | Dehorning  | Decrease pain and increase calf productivity | controlled     | 12  | Positive  |

|           |                         |        |              |   |                |     |          |
|-----------|-------------------------|--------|--------------|---|----------------|-----|----------|
| Meloxicam | Heinrich et al. 2010    | Cattle | Dehorning    | Decrease pain and stress                | controlled     | 60  | Positive |
| Meloxicam | Heinrich et al. 2009    | Cattle | Dehorning    | Decrease stress                         | not controlled | 60  | Positive |
| Meloxicam | Bates et al. 2015       | Cattle | Dehorning    | Increase calf productivity              | controlled     | 202 | Positive |
| Meloxicam | Roy et al. 2015         | Cattle | General      | Decrease inflammation                   | controlled     | 12  | Positive |
| Meloxicam | Carpenter et al. 2016   | Cattle | General      | Increase cow productivity and longevity | controlled     | .   | Positive |
| Meloxicam | Amiridis et al. 2009    | Cattle | General      | Increase pregnancy rate                 | controlled     | 402 | Positive |
| Meloxicam | Cooke et al. 2016       | Cattle | Handling     | Decrease stress                         | controlled     | 943 | None     |
| Meloxicam | Guarnieri et al. 2014   | Cattle | Handling     | Decrease stress                         | controlled     | 84  | Positive |
| Meloxicam | Van Engen et al. 2016   | Cattle | Handling     | Decrease stress                         | controlled     | 87  | Positive |
| Meloxicam | Van Engen et al. 2014   | Cattle | Handling     | Decrease stress                         | not controlled | 97  | Positive |
| Meloxicam | Maslanka et al. 2011    | Cattle | Immunisation | Avoid dysfunction                       | controlled     | 10  | None     |
| Meloxicam | Rodrigues et al. 2015   | Cattle | Immunisation | Avoid dysfunction                       | controlled     | 21  | None     |
| Meloxicam | Bednarek et al. 2002    | Cattle | Infection    | Decrease inflammation                   | not controlled | .   | Positive |
| Meloxicam | Konigsson et al. 2002   | Cattle | Infection    | Decrease inflammation                   | not controlled | 4   | Positive |
| Meloxicam | Bednarek et al. 2003a   | Cattle | Infection    | Improve recovery                        | not controlled | 30  | Positive |
| Meloxicam | Todd et al. 2010        | Cattle | Infection    | Increase calf productivity              | controlled     | 62  | Positive |
| Meloxicam | Bednarek et al. 2003b   | Cattle | Infection    | Increase immune response                | controlled     | 18  | Positive |
| Meloxicam | Bednarek et al. 2005    | Cattle | Infection    | Increase immune response                | not controlled | 30  | Mixed    |
| Meloxicam | Coetzee et al. 2014     | Cattle | Limb injury  | Decrease pain                           | controlled     | 18  | Positive |
| Meloxicam | Offinger et al. 2013    | Cattle | Limb injury  | Decrease pain                           | controlled     | 19  | Positive |
| Meloxicam | Barrier et al. 2014     | Cattle | Reproduction | Decrease pain                           | controlled     | 110 | Positive |
| Meloxicam | Fitzpatrick et al. 2013 | Cattle | Reproduction | Decrease pain                           | controlled     | 24  | Positive |

|           |                        |        |              |                          |                |     |          |
|-----------|------------------------|--------|--------------|--------------------------|----------------|-----|----------|
| Meloxicam | Newby et al. 2013b     | Cattle | Reproduction | Decrease pain and stress | controlled     | 103 | Positive |
| Meloxicam | Mainau et al. 2015     | Cattle | Reproduction | Decrease pain and stress | not controlled | 60  | Mixed    |
| Meloxicam | McDougall et al. 2009  | Cattle | Reproduction | Improve recovery         | not controlled | 727 | Positive |
| Meloxicam | Lopes et al. 2015      | Cattle | Reproduction | Increase pregnancy rate  | controlled     | 85  | Positive |
| Meloxicam | Aguiar et al. 2013     | Cattle | Reproduction | Increase pregnancy rate  | controlled     | 207 | Positive |
| Meloxicam | Rajkumar et al. 2010   | Cattle | Reproduction | Increase pregnancy rate  | not controlled | .   | Positive |
| Meloxicam | Erdem et al. 2010      | Cattle | Reproduction | No complications         | controlled     | 87  | Negative |
| Meloxicam | Hirsch et al. 2009     | Cattle | Reproduction | No complications         | controlled     | 41  | Positive |
| Meloxicam | Newby et al. 2014      | Cattle | Reproduction | No complications         | controlled     | .   | Positive |
| Meloxicam | Beausoleil et al. 2012 | Cattle | Surgery      | Decrease pain            | controlled     | 18  | None     |
| Meloxicam | Blois et al. 2010      | Dog    | General      | Avoid dysfunction        | controlled     | 10  | Positive |
| Meloxicam | Wooten et al. 2009     | Dog    | General      | Avoid dysfunction        | not controlled | 8   | Positive |
| Meloxicam | Punke et al. 2008      | Dog    | General      | Avoid dysfunction        | not controlled | 8   | Positive |
| Meloxicam | Gilmour et al. 2012    | Dog    | General      | Decrease inflammation    | controlled     | 15  | None     |
| Meloxicam | Gilmour et al. 2009    | Dog    | General      | Decrease inflammation    | not controlled | 38  | Positive |
| Meloxicam | Hare et al. 2013       | Dog    | General      | No complications         | controlled     | 40  | Mixed    |
| Meloxicam | Bostrom et al. 2006    | Dog    | General      | No complications         | controlled     | 8   | Positive |
| Meloxicam | Boston et al. 2003     | Dog    | General      | No complications         | controlled     | 20  | Positive |
| Meloxicam | Narita et al. 2006     | Dog    | General      | No complications         | not controlled | 15  | Positive |
| Meloxicam | Fusellier et al. 2008  | Dog    | General      | No complications         | not controlled | 10  | Positive |
| Meloxicam | Viking et al. 2002     | Dog    | Infection    | Decrease pain            | controlled     | 12  | Positive |
| Meloxicam | Brainard et al. 2007   | Dog    | Limb injury  | Avoid dysfunction        | not controlled | 8   | Positive |

|           |                         |     |             |  |                |     |          |
|-----------|-------------------------|-----|-------------|--|----------------|-----|----------|
| Meloxicam | Cross et al. 1997       | Dog | Limb injury | Decrease inflammation                      | not controlled | 12  | Positive |
| Meloxicam | Van Bree et al. 1994    | Dog | Limb injury | Decrease inflammation and no complications | controlled     | 4   | Positive |
| Meloxicam | Jones et al. 2002       | Dog | Limb injury | Decrease pain                              | controlled     | 12  | Positive |
| Meloxicam | Moreau et al. 2003      | Dog | Limb injury | Decrease pain                              | controlled     | 71  | Positive |
| Meloxicam | Matyas et al. 2013      | Dog | Limb injury | Decrease pain                              | controlled     | 11  | Positive |
| Meloxicam | Borer et al. 2003       | Dog | Limb injury | Decrease pain                              | controlled     | 60  | Positive |
| Meloxicam | Cozzi and Spensley      | Dog | Limb injury | Decrease pain and inflammation             | controlled     | 280 | Positive |
| Meloxicam | Schmid et al. 2010      | Dog | Limb injury | Decrease pain and inflammation             | controlled     | .   | Positive |
| Meloxicam | Walton et al. 2014      | Dog | Limb injury | Decrease pain and inflammation             | controlled     | 111 | Positive |
| Meloxicam | Peterson and Keefe 2004 | Dog | Limb injury | Decrease pain and no complications         | controlled     | 217 | Positive |
| Meloxicam | Nell et al. 2002        | Dog | Limb injury | Decrease pain and no complications         | controlled     | 214 | Positive |
| Meloxicam | Doig et al. 2000        | Dog | Limb injury | Decrease pain and no complications         | controlled     | 40  | Positive |
| Meloxicam | Sauve et al. 2003       | Dog | Limb injury | No complications                           | controlled     | 46  | Positive |
| Meloxicam | Mullins et al. 2012     | Dog | Surgery     | Avoid dysfunction                          | not controlled | .   | Mixed    |
| Meloxicam | Budsberg et al. 2002    | Dog | Surgery     | Decrease pain                              | controlled     | 40  | Positive |
| Meloxicam | Zanuzzo et al. 2015     | Dog | Surgery     | Decrease pain                              | controlled     | 40  | Positive |
| Meloxicam | Teixeira et al. 2013    | Dog | Surgery     | Decrease pain                              | controlled     | 27  | Positive |
| Meloxicam | Tsai et al. 2013        | Dog | Surgery     | Decrease pain                              | controlled     | 27  | Positive |

|           |                             |          |             |  |                |       |          |
|-----------|-----------------------------|----------|-------------|--|----------------|-------|----------|
| Meloxicam | Teixeira et al. 2013        | Dog      | Surgery     | Decrease pain                          | controlled     | 24    | Positive |
| Meloxicam | Leece et al. 2005           | Dog      | Surgery     | Decrease pain                          | controlled     | 43    | Positive |
| Meloxicam | Fowler et al. 2003          | Dog      | Surgery     | Decrease pain                          | controlled     | 20    | Positive |
| Meloxicam | Caulkett et al. 2003        | Dog      | Surgery     | Decrease pain                          | controlled     | 15    | Positive |
| Meloxicam | Moak et al. 2011            | Dog      | Surgery     | Decrease pain                          | not controlled | 25    | None     |
| Meloxicam | Gruet et al. 2011           | Dog      | Surgery     | Decrease pain and inflammation         | controlled     | 146   | Positive |
| Meloxicam | Lafuente et al. 2005        | Dog      | Surgery     | Decrease pain and inflammation         | controlled     | 16    | Positive |
| Meloxicam | Yilmaz et al. 2014          | Dog      | Surgery     | Decrease stress                        | not controlled | 24    | Positive |
| Meloxicam | Nakagawa et al. 2007        | Dog      | Surgery     | Increase recovery and no complications | controlled     | 5     | Positive |
| Meloxicam | Kum et al. 2013             | Dog      | Surgery     | No complications                       | controlled     | 18    | Positive |
| Meloxicam | Kazakos et al. 2005         | Dog      | Surgery     | No complications                       | controlled     | 38    | Positive |
| Meloxicam | Fresno et al. 2005          | Dog      | Surgery     | No complications                       | not controlled | 20    | Positive |
| Meloxicam | Laredo et al. 2004          | Dog      | Surgery     | No complications                       | not controlled | 32    | Positive |
| Meloxicam | Gruet et al. 2013           | Dog      | Surgery     | Decrease pain and inflammation         | not controlled | 174   | Positive |
| Meloxicam | Mathews et al. 2001         | Dog      | Surgery     | Decrease pain and no complications     | controlled     | 36    | Positive |
| Meloxicam | Khan and McLean 2012        | Dog, cat | General     | No complications                       | controlled     | 22206 | Mixed    |
| Meloxicam | Regan et al. 2016           | Donkey   | Limb injury | Decrease pain and inflammation         | controlled     | 40    | Mixed    |
| Meloxicam | Ingvast-Larsson et al. 2011 | Goat     | Dehorning   | Decrease pain                          | not controlled | 11    | None     |

|           |                           |               |              |                                |                |        |               |
|-----------|---------------------------|---------------|--------------|--------------------------------|----------------|--------|---------------|
| Meloxicam | van der Heide et al. 2008 | Goat          | Limb injury  | No complications               | controlled     | 18     | Positive      |
| Meloxicam | Little et al. 2007        | Horse         | General      | Avoid dysfunction              | controlled     | 18     | Positive      |
| Meloxicam | Beretta et al. 2005       | Horse         | General      | Decrease pain and inflammation | controlled     | .      | Positive      |
| Meloxicam | Raidal et al. 2014        | Horse         | General      | No complications               | controlled     | 9      | Mixed         |
| Meloxicam | Nobel et al. 2012         | Horse         | General      | No complications               | controlled     | 33     | Positive      |
| Meloxicam | D'Arcy-Moskwa et al. 2012 | Horse         | General      | No complications               | controlled     | 25     | Positive      |
| Meloxicam | Raidal et al. 2013        | Horse         | General      | No complications               | controlled     | 10     | Positive      |
| Meloxicam | Vander Werf et al. 2012   | Horse         | General      | No complications               | not controlled | 7      | Positive      |
| Meloxicam | Brideau et al. 2001       | Horse,<br>Dog | General      | Decrease inflammation          | controlled     | 30, 48 | Positive      |
| Meloxicam | de Walter et al. 2016     | Horse         | Limb injury  | Decrease inflammation          | controlled     | 24     | No conclusion |
| Meloxicam | de Grauw et al. 2009      | Horse         | Limb injury  | Decrease pain and inflammation | controlled     | 6      | Positive      |
| Meloxicam | Lima et al. 2015          | Horse         | Reproduction | Increase pregnancy rate        | controlled     | 11     | Negative      |
| Meloxicam | Naylor et al. 2014        | Horse         | Surgery      | Decrease pain                  | controlled     | 60     | Mixed         |
| Meloxicam | Walliser et al. 2015      | Horse         | Surgery      | Decrease pain and inflammation | controlled     | 66     | Positive      |
| Meloxicam | Paull et al. 2012         | Sheep         | Castration   | Decrease pain                  | controlled     | 48     | Positive      |
| Meloxicam | Small et al. 2014         | Sheep         | Castration   | Decrease pain                  | controlled     | 60     | Positive      |
| Meloxicam | Colditz et al. 2011       | Sheep         | Limb injury  | Decrease pain and inflammation | controlled     | .      | Positive      |
| Meloxicam | McKeown et al. 2000       | Sheep         | Reproduction | Increase pregnancy rate        | controlled     | .      | Positive      |
| Meloxicam | Dorniak et al. 2011       | Sheep         | Reproduction | No complications               | controlled     | .      | Negative      |

|           |                      |        |              |                                    |                |    |               |
|-----------|----------------------|--------|--------------|------------------------------------|----------------|----|---------------|
| Meloxicam | Rac et al. 2007      | Sheep  | Reproduction | No complications                   | controlled     | .  | Positive      |
| Meloxicam | Barrett et al. 2016  | Cattle | Surgery      | Decrease pain                      | controlled     | 24 | No conclusion |
| Meloxicam | Newby et al. 2013    | Cattle | Surgery      | Decrease pain                      | not controlled | 10 | Positive      |
| Meloxicam | Deneuche et al. 2004 | Dog    | General      | Decrease pain and no complications | controlled     | 60 | Positive      |
| Meloxicam | Forsyth et al. 1998  | Dog    | General      | No complications                   | not controlled | 24 | Positive      |
| Meloxicam | Luna et al. 2007     | Dog    | General      | No complications                   | not controlled | 36 | Positive      |